Aurinia Pharmaceuticals Inc. AUPH 深 沪
交易中 07-07 11:30:49 美东时间
16.00
+0.510
+3.29%
华盛通- 最 高16.13
- 今 开15.60
- 成交量 46.32万股
- 最 低 15.42
- 昨 收 15.49
- 总市值 20.58亿
- 52周最高 19.25
- 市盈率 静 7.73
- 换手率 0.00%
- 52周最低 8.55
- 委 比 94.80%
- 总股本 1.29亿
- 历史最高 33.972
- 量 比 0.71
- 振 幅 4.58%
- 历史最低 1.41
- 每 手 1
- 风险率 2.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
06-13 00:34
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death
Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in
06-04 19:13
Tang Capital takes 10% stake in Aurinia Pharma
Tang Capital Management Tuesday said that it acquired 206,005 common shares of Aurinia Pharmaceuticals (AUPH) at a price of $15.28 per share for an aggregate purchase price of $3.1M. As a result of th...
06-03 15:54
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 financial results and affirmed FY26 sales guidance below estimates.
Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 finan...
05-07 22:38
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $326.190M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $326.190 million estimate.
05-07 21:36
Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 56.25 percent increase over earnings of $0.16 per share
05-07 20:14
